Dendrite Helps Pharmaceutical Sales Reps Average Seven More Product Briefings Per Week, Industry Study Concludes.

Study shows how pharmaceutical companies with 1,000 sales representatives could reap $74 million in incremental annual revenues

BEDMINSTER, N.J. -- Dendrite's flagship Sales Force Effectiveness product, Mobile Intelligence[TM], enables sales representatives to achieve seven more product briefings - known as "product details" - with physicians on a weekly basis, when compared to an industry average, according to a study by Health Industry Insights, an IDC company.

For a typical life sciences company with 1,000 sales representatives, this finding can translate into $74 million of incremental annual revenues, the study shows.

The study, which compared Dendrite's flagship product with an industry average of other Sales Force Effectiveness products, also identified other quantitative benefits of Mobile Intelligence for sales representatives, including time savings and reduced duplicate records. The study also found higher job satisfaction and a better quality of life among these sales reps.

The efficiencies gained from using Mobile Intelligence are a direct result of the software's unique user experience. To develop this solution, Dendrite closely monitored how pharmaceutical sales representatives interacted in the field and redesigned its software to precisely mirror the specific needs of the representative throughout their work flow. As a result, sales representatives spend less time interacting with their software, and more time interacting with prescribers.

"Because we are a leading company focused on the life sciences industry, we are in a unique position to craft a solution that's perfectly aligned to it," said Mark Theilken, president, U.S. Sales Solutions. "The life science industry has substantially different needs, and we believe our approach is much better than trying to retrofit a more generic, horizontal solution."

Results of this study will be presented Thursday at Dendrite's PharmaQuest conference, "Putting You Ahead: Success Strategies for Mid-Tier and Emerging Life Sciences Companies." To register for PharmaQuest, visit www.dendrite.com/pharmaquest. To receive a white paper illustrating the study results in greater detail, visit www.dendrite.com/moredetails.

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. Dendrite's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.